Clinical Trial Update: A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of droxidopa for neurogenic orthostatic hypotension has completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Failure
• Dopamine Beta-hydroxylase Deficiency
• Neurogenic Orthostatic Hypotension
• Non-diabetic Neuropathy

Drugs mentioned

• Northera (droxidopa)

Snippet

Sponsor: Chelsea Therapeutics | Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Status: COMPLETED | Results posted: 2014-05-16